Unlike wet AMD, to date there is no effective treatment for dry AMD, and while anti-vascular endothelial growth factor (VEGF) therapy has been reasonably successful in the short term, vision gains are not maintained at 5 years after starting treatment, and many patients ultimately progress to GA [8]. Here, VEGFA is linked to dry age related macular degeneration.